Ljubljana, Slovenia

Andreja Vukmirovic

This inventor holds 2 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignee: Lek Pharmaceuticals D.d.. Active years: 2009-2014.




Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2009-2014

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Andreja Vukmirovic: Innovator in Pharmaceutical Composition

Introduction

Andreja Vukmirovic is a notable inventor based in Ljubljana, Slovenia. He has made significant contributions to the field of pharmaceuticals, particularly in the stabilization of erythropoietin (EPO) compositions. With a total of 2 patents, Vukmirovic's work is recognized for its innovative approach to drug formulation.

Latest Patents

Vukmirovic's latest patents include a stable pharmaceutical composition comprising erythropoietin. The first patent presents a new stable pharmaceutical composition of EPO that is stabilized with PVP. The second patent also focuses on a stable pharmaceutical composition of EPO, which is stabilized using a combination of a poloxamer polyol and a polyhydric alcohol. These inventions aim to enhance the stability and efficacy of EPO, which is crucial for various medical applications.

Career Highlights

Vukmirovic is currently associated with Lek Pharmaceuticals D.d., a prominent company in the pharmaceutical industry. His work at Lek Pharmaceuticals has allowed him to explore innovative solutions in drug formulation, contributing to the advancement of pharmaceutical sciences.

Collaborations

Some of his notable coworkers include Jelka Svetek and Tanja Rozman Peterka. Their collaboration has likely fostered a creative environment that encourages innovation and the development of new pharmaceutical solutions.

Conclusion

Andreja Vukmirovic's contributions to the field of pharmaceuticals, particularly through his patents on erythropoietin compositions, highlight his role as an innovator. His work continues to impact the pharmaceutical industry positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…